00:00 / 00:00
Thrombolytics, also called clot busters, are medications that break up clots, and are used for the short-term emergency management of thrombotic conditions, such as myocardial infarction, pulmonary embolism, ischemic stroke, and thrombosis of prosthetic heart valves and stents.
Now, thrombolytics are usually derived from enzymes involved in fibrinolysis, or the gradual degradation of the fibrin mesh. These include alteplase, reteplase, and tenecteplase, which are derived from tissue plasminogen activator, or tPA, through recombinant DNA technology, and act locally at the clot site.
Thrombolytics are given intravenously. Once in the blood, they act on a protein produced by the liver called plasminogen, and convert it into its active form called plasmin.
These medications directly bind to fibrin proteins in the clot and preferentially act on plasminogen trapped in the fibrin mesh, also called fibrin-bound plasminogen. The resulting plasmin then acts as a protease and cuts the fibrin into smaller pieces.
This allows the trapped red blood cells and platelets to float away, dissolving the clot.The main side effect of all thrombolytics is undue bleeding from other sites, including the injection site, gastrointestinal bleeds, and hemorrhagic stroke.
In severe cases, thrombolytic-associated bleeding can be treated with medications like aminocaproic acid, which acts by binding to plasminogen and plasmin, ultimately inhibiting their action on fibrin.
If aminocaproic acid fails, other transfusion products can be administered, such as platelets or coagulation factors in the form of fresh frozen plasma.
Thrombolytics, also known as clot-busting drugs, are a class of medications that are used to dissolve blood clots. These drugs work by converting plasminogen to plasmin, an enzyme that breaks down fibrin, a protein that forms the backbone of blood clots. By breaking down fibrin, thrombolytics can dissolve blood clots and restore blood flow to the affected area.
Thrombolytics include drugs like alteplase, reteplase, and tenecteplase, typically given for the acute management of pathological blood clots like in embolic or thrombotic strokes. The main side effect of thrombolytics is undue bleeding from other sites, including injection sites, gastrointestinal bleeding, and hemorrhagic stroke. This is why they are contraindicated in hemorrhagic strokes and head trauma.
Nursing considerations when administering thrombolytics include conducting a thorough baseline assessment, monitoring for side effects, and evaluating the therapeutic response. Client teaching is centered around minimizing bleeding and bruising, as well as recognizing signs and symptoms of bleeding or additional clot formation.
Latest on COVID-19
Nurse Practitioner (NP)
Physician Assistant (PA)
Create custom content
Raise the Line Podcast
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Cookies are used by this site.
Terms and Conditions
USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.